These biomarkers reflect the underlying immunopathology driven by cytokines such as interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13), which are key therapeutic targets in modern asthma management. Here, IL13 is linked to asthma.